vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Sinclair, Inc. (SBGI). Click either name above to swap in a different company.

Sinclair, Inc. is the larger business by last-quarter revenue ($807.0M vs $622.0M, roughly 1.3× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 2.5%, a 32.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.0%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -1.3%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Sinclair, Inc., doing business as Sinclair Broadcast Group, is a publicly traded American telecommunications conglomerate that is controlled by the descendants of company founder Julian Sinclair Smith. Headquartered in the Baltimore suburb of Cockeysville, Maryland, the company is the second-largest television station operator in the United States by number of stations after Nexstar Media Group, owning or operating 193 stations across the country in over 100 markets, covering 40% of American ...

RPRX vs SBGI — Head-to-Head

Bigger by revenue
SBGI
SBGI
1.3× larger
SBGI
$807.0M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+0.8% gap
RPRX
4.8%
4.0%
SBGI
Higher net margin
RPRX
RPRX
32.0% more per $
RPRX
34.4%
2.5%
SBGI
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-1.3%
SBGI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RPRX
RPRX
SBGI
SBGI
Revenue
$622.0M
$807.0M
Net Profit
$214.2M
$20.0M
Gross Margin
Operating Margin
62.4%
0.0%
Net Margin
34.4%
2.5%
Revenue YoY
4.8%
4.0%
Net Profit YoY
2.9%
EPS (diluted)
$0.49
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
SBGI
SBGI
Q1 26
$807.0M
Q4 25
$622.0M
$836.0M
Q3 25
$609.3M
$773.0M
Q2 25
$578.7M
$784.0M
Q1 25
$568.2M
$776.0M
Q4 24
$593.6M
$1.0B
Q3 24
$564.7M
$917.0M
Q2 24
$537.3M
$829.0M
Net Profit
RPRX
RPRX
SBGI
SBGI
Q1 26
$20.0M
Q4 25
$214.2M
$109.0M
Q3 25
$288.2M
$-1.0M
Q2 25
$30.2M
$-64.0M
Q1 25
$238.3M
$-156.0M
Q4 24
$208.2M
$176.0M
Q3 24
$544.0M
$94.0M
Q2 24
$102.0M
$17.0M
Operating Margin
RPRX
RPRX
SBGI
SBGI
Q1 26
0.0%
Q4 25
62.4%
9.6%
Q3 25
70.1%
7.5%
Q2 25
36.3%
2.7%
Q1 25
94.0%
1.8%
Q4 24
60.9%
26.5%
Q3 24
19.5%
Q2 24
50.2%
7.7%
Net Margin
RPRX
RPRX
SBGI
SBGI
Q1 26
2.5%
Q4 25
34.4%
13.0%
Q3 25
47.3%
-0.1%
Q2 25
5.2%
-8.2%
Q1 25
41.9%
-20.1%
Q4 24
35.1%
17.5%
Q3 24
96.3%
10.3%
Q2 24
19.0%
2.1%
EPS (diluted)
RPRX
RPRX
SBGI
SBGI
Q1 26
$0.28
Q4 25
$0.49
$1.62
Q3 25
$0.67
$-0.02
Q2 25
$0.07
$-0.91
Q1 25
$0.55
$-2.30
Q4 24
$0.46
$2.64
Q3 24
$1.21
$1.43
Q2 24
$0.23
$0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
SBGI
SBGI
Cash + ST InvestmentsLiquidity on hand
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
Total Assets
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
$618.7M
$866.0M
Q3 25
$938.9M
$526.0M
Q2 25
$631.9M
$616.0M
Q1 25
$1.1B
$631.0M
Q4 24
$929.0M
$697.0M
Q3 24
$950.1M
$536.0M
Q2 24
$1.8B
$378.0M
Total Debt
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
$9.0B
$4.4B
Q3 25
$8.9B
$4.1B
Q2 25
$8.0B
$4.1B
Q1 25
$7.6B
$4.2B
Q4 24
$7.6B
$4.1B
Q3 24
$7.6B
$4.1B
Q2 24
$7.6B
$4.1B
Stockholders' Equity
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
$9.7B
$443.0M
Q3 25
$9.6B
$347.0M
Q2 25
$9.5B
$361.0M
Q1 25
$9.8B
$436.0M
Q4 24
$10.3B
$583.0M
Q3 24
$10.3B
$415.0M
Q2 24
$9.8B
$340.0M
Total Assets
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
$19.6B
$5.9B
Q3 25
$19.3B
$5.6B
Q2 25
$18.3B
$5.7B
Q1 25
$17.6B
$5.8B
Q4 24
$18.2B
$5.9B
Q3 24
$18.0B
$5.8B
Q2 24
$17.7B
$5.7B
Debt / Equity
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
0.92×
9.84×
Q3 25
0.93×
11.75×
Q2 25
0.84×
11.30×
Q1 25
0.78×
9.56×
Q4 24
0.74×
7.02×
Q3 24
0.74×
9.86×
Q2 24
0.78×
12.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
SBGI
SBGI
Operating Cash FlowLast quarter
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
1.7%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
$827.1M
$98.0M
Q3 25
$702.6M
$-36.0M
Q2 25
$364.0M
$122.0M
Q1 25
$596.1M
$5.0M
Q4 24
$742.5M
$198.0M
Q3 24
$703.6M
$210.0M
Q2 24
$658.2M
$-306.0M
Free Cash Flow
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
$79.0M
Q3 25
$-58.0M
Q2 25
$105.0M
Q1 25
$-11.0M
Q4 24
$175.0M
Q3 24
$193.0M
Q2 24
$-329.0M
FCF Margin
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
9.4%
Q3 25
-7.5%
Q2 25
13.4%
Q1 25
-1.4%
Q4 24
17.4%
Q3 24
21.0%
Q2 24
-39.7%
Capex Intensity
RPRX
RPRX
SBGI
SBGI
Q1 26
1.7%
Q4 25
2.3%
Q3 25
2.8%
Q2 25
2.2%
Q1 25
2.1%
Q4 24
2.3%
Q3 24
1.9%
Q2 24
2.8%
Cash Conversion
RPRX
RPRX
SBGI
SBGI
Q1 26
Q4 25
3.86×
0.90×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
3.57×
1.13×
Q3 24
1.29×
2.23×
Q2 24
6.45×
-18.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

SBGI
SBGI

Media revenue$701.0M87%
Other$82.0M10%
Political advertising revenue$18.0M2%
Non-media revenue$6.0M1%

Related Comparisons